Established Sell-Side M&A Leadership

Tombstones for these transactions: Smile Doctors/Thomas H Lee, BioAgilytix/Cinven, Norwood Medical/Heraeus, Veterinary Practice Partners/Audax Group, Vera Whole Health, and Andelyn/Pall Corporation
  • Activity was strong across multiple segments of healthcare services, including multi-site healthcare, pharmaceutical services, outsourced medical manufacturing, and other specialty provider groups
  • 2021 was a record year for sell-side M&A activity and our pipeline points to continued robust activity in 2022

Trusted Buy-Side Advice to Clients

Tombstones for these transactions: Recro Pharma/IriSys, CVC/Rayner, SummaEquity/G-Con Manufacturing, Oak Hill Capital/Technimark, Livingbridge/Everlight Radiology, and Vitruvian/Koas
  • Our deep insight across healthcare services provides invaluable, strategic perspectives and buy-side intelligence to our clients
  • Clients value our thoughtful, post-deal M&A road mappings
  • Drawing on multiple decades of transaction structuring and execution experience, we guide buyers to optimize price and terms

Continued Momentum in Equity and Debt Capital Markets

Tombstones for these transactions: LifeStance Health, P3 Health Partners, Privia Health, Agilon Health, Andelyn Ecosciences, and Alignment Healthcare
  • We served as a bookrunner on 21 of 2021’s successful healthcare services equity offerings
  • Our transaction scope in 2021 has included IPO’s, follow-on equity offerings, convertible debt, and private equity placements

Learn more about our healthcare services investment banking expertise.